Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
The fair value estimate for LENZ Therapeutics has been revised from US$53.71 to US$32.00, signaling a reset in where analysts currently see the stock’s potential. Recent commentary shows a more mixed stance, with some analysts still highlighting long term upside while others point to execution risks and valuation resets behind these target cuts, including references to US$20, US$8 and US$10 levels. As you read on, you will see how these shifting price targets fit into the broader LENZ Therapeutics story and what to watch as the narrative evolves.
What Wall Street Has Been Saying 🐂 Bullish Takeaways
Citi maintains a Buy rating on LENZ Therapeutics even after revising its price target to US$20 from US$26, which signals that the firm still sees upside potential relative to recent trading levels.
Recent target changes, including the Citi revision, suggest analysts continue to assign value to LENZ Therapeutics based on its longer term growth prospects, while adjusting for updated assumptions.
🐻 Bearish Takeaways
H.C. Wainwright has cut its price target on LENZ Therapeutics more than once, with reductions of US$10 and US$8 cited in recent reports, which points to a more cautious stance on execution and valuation risk.
Piper Sandler recently downgraded LENZ Therapeutics, and William Blair removed the stock from its Analyst Conviction List, both actions reinforcing a cooler sentiment around near term risk and return trade offs.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!
NasdaqGS:LENZ 1-Year Stock Price Chart
We’ve flagged 1 risk for LENZ Therapeutics. See which could impact your investment.
How This Changes the Fair Value For LENZ Therapeutics
Fair value revised from US$53.71 to US$32.00.
Projected revenue growth rate adjusted from 126.49% to 100.47%.
Expected net profit margin adjusted from 13.30% to 19.40%.
Future P/E multiple revised from 93.18x to 45.56x.
Discount rate updated from 6.96% to 7.11%.
Never Miss an Update: Follow The Narrative
Narratives link LENZ Therapeutics’ business story to a financial forecast and fair value, updating as new data and research come through. They help you see how product launches, spending, and risks come together in a single, coherent view.
Head over to the Simply Wall St Community and follow the Narrative on LENZ Therapeutics to stay up to date on:
How the launch of VIZZ for presbyopia, along with telehealth and eye care professional adoption, could shape LENZ Therapeutics’ early commercial phase.
The planned shift to a consumer focused marketing push, including the Sarah Jessica Parker campaign and ex U.S. licensing deals in markets such as China, Canada, Australia, and New Zealand.
Key execution risks, from high upfront SG&A spend and uncertain long term patient uptake to potential hurdles in tolerability, direct to consumer response, and overseas regulatory or commercial outcomes.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include LENZ.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com